The E100: Ex­tend­ing run­ways, dump­ing drugs, fac­tor­ing in a bank­ing cri­sis and grap­pling with the IRA — there's a lot for biotech ex­ecs to deal with

If there’s one ma­jor theme play­ing out in biotech this year, it’s watch­ing out for the pit­falls. And then get­ting hit out of left field …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.